Abstract: A process for preparing a particle comprising a biological molecule typically a DNA plasmid, and a carrier polymer, typically poly-lactic acid (PLA), in which an organic solvent solution of the biological molecule and the carrier polymer in an organic solvent medium, nearly saturated with the biological molecule, is prepared, then this solution is contacted with an antisolvent substance, typically supercritical carbon dioxide to separate a particle comprising the biological molecule and the carrier polymer. High loadings of the biological molecule in the particle can be achieved.
Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.
Abstract: Antigen binding proteins that bind ?-amyloid peptide, in particular human ?-amyloid peptide; methods of treating diseases or disorders characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, including age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.
Type:
Grant
Filed:
December 9, 2008
Date of Patent:
December 30, 2014
Assignee:
Glaxo Group Limited
Inventors:
Philippe Marc Louis Alard, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Gerald Wayne Gough, Alan Peter Lewis, Peter Ernest Soden, Pamela Joan Thomas, Trevor Anthony Kenneth Wattam
Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Type:
Grant
Filed:
November 21, 2011
Date of Patent:
December 23, 2014
Assignee:
Glaxo Group Limited
Inventors:
Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
Type:
Grant
Filed:
September 20, 2011
Date of Patent:
October 28, 2014
Assignee:
Glaxo Group Limited
Inventors:
Zehong Wan, Xiaomin Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
Abstract: A process for separating a compound from solution in organic solvent by a chromatographic process, in particular liquid-liquid chromatography, in which prior to the chromatographic process the composition of the solution is changed by means of a process of organic solvent nanofiltration for a solvent exchange. Additionally or alternatively subsequent to the chromatographic process the output from the chromatographic process is subjected to a process of organic solvent nanofiltration to remove residual target compound and/or impurities in the output for solvent recovery.
Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
Abstract: The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with antigen binding proteins that bind ?-amyloid peptide and in particular human ?-amyloid peptide.
Type:
Grant
Filed:
September 23, 2008
Date of Patent:
October 14, 2014
Assignee:
Glaxo Group Limited
Inventors:
Stephen Anthony Burbidge, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the GPR38 receptor.
Type:
Grant
Filed:
April 2, 2009
Date of Patent:
October 7, 2014
Assignee:
Glaxo Group Limited
Inventors:
Darren Jason Mitchell, Jonathan Thomas Seal, Mervyn Thompson, Susan Marie Westaway, Samantha Louisa Brown
Abstract: This invention relates to methods for determining the activity of Lp-PLA2 in at least one sample from an animal. The invention also relates to methods for determining the inhibition of Lp-PLA2 activity in samples from animals that are administered an Lp-PLA2 inhibitor.
Type:
Grant
Filed:
June 17, 2010
Date of Patent:
September 30, 2014
Assignee:
Glaxo Group Limited
Inventors:
Yaping Shou, Yin-Fai Siu, George T. Walker
Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3 alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
Type:
Application
Filed:
June 4, 2014
Publication date:
September 25, 2014
Applicant:
GLAXO GROUP LIMITED
Inventors:
JULIA CASTRO PICHEL, RAQUEL FERNANDEZ MENENDEZ, ESTHER PILAR FERNANDEZ VELANDO, SILVIA GONZALEZ DEL VALLE, ARACELI MALLO-RUBIO
Abstract: One aspect provides a drug dispenser device comprising a housing; extending from the housing, an outlet for insertion into a body cavity of a patient; provided to the housing and moveable with respect thereto, a drug discharge device having a longitudinal axis and comprising a container for storing a drug formulation to be dispensed, a discharge mechanism and a discharge channel from the container for discharge of the drug formulation to the outlet; connecting to the container, a container collar connected to the discharge device; connecting to the container collar and moveable with respect thereto along the longitudinal axis of the drug discharge device; connecting to the container collar and moveable with respect thereto along the longitudinal axis of the drug discharge device, a transfer element including an actuating portion; provided to the housing, at least one finger operable member moveable to apply an actuating force to the actuating portion of the transfer element to move the transfer element from a
Abstract: Disclosed are crystalline forms of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione benzenesulfonate salt and pharmaceutical compositions thereof. Also disclosed are processes for the preparation the above compounds and methods for use thereof.
Type:
Grant
Filed:
March 18, 2014
Date of Patent:
August 26, 2014
Assignee:
Glaxo Group Limited
Inventors:
Richard Bellingham, Andrew Mark Buswell, Victoria Ironmonger, Michael Urquhart
Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.
Type:
Application
Filed:
November 18, 2013
Publication date:
August 14, 2014
Applicant:
GLAXO GROUP LIMITED
Inventors:
Bruce Hamilton, Christopher Herring, Mark Andrew Paulik